InMed Announces Appointment of Chief Operating Officer
July 18 2022 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:
INM), a leader in the research, development, manufacturing and
commercialization of rare cannabinoids, today announces Michael
Woudenberg has been appointed Chief Operating Officer of the
Company, overseeing all day-to-day operations.
Mr. Woudenberg was previously Senior Vice
President of Chemistry, Manufacturing and Controls. Mike has been
an integral part of the executive team for the last four years,
supporting multiple functions within the organisation. Prior to
joining InMed, Mike had over 20 years of successful drug
development, process engineering, GMP manufacturing and general
management experience at all levels of various companies. Mike’s
intimate knowledge of the Company’s operations and extensive
leadership experience make him an ideal candidate to oversee
operations and support the long-term strategic growth of the
Company. He will continue to report to Eric A. Adams, InMed
President and CEO.
Mr. Adams commented, “I would like to
congratulate Mike for his well-deserved promotion to Chief
Operating Officer of InMed. Mike has been involved in all facets of
operations over the last four years and is a natural fit to oversee
day-to-day operations.”
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancyVice President,
Investor Relations & Corporate CommunicationsT:
+1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively,
"forward-looking information") within the meaning of applicable
securities laws. Forward-looking information is based on
management's current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: being a global leader in the research,
development, manufacturing and development of rare cannabinoids;
and delivering new treatment alternatives to patients that may
benefit from cannabinoid-based pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous assumptions
regarding, among other things: the ability to obtain all necessary
regulatory approvals on a timely basis, or at all; and continued
economic and market stability. While InMed considers these
assumptions to be reasonable, these assumptions are inherently
subject to significant business, economic, competitive, market and
social uncertainties and contingencies.Additionally, there are
known and unknown risk factors which could cause InMed's actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking information contained herein. A
complete discussion of the risks and uncertainties facing InMed’s
stand-alone business is disclosed in InMed’s Annual Report on Form
10-K and other filings with the Security and Exchange Commission on
www.sec.gov.All forward-looking information herein is qualified in
its entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jun 2024 to Jul 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Jul 2023 to Jul 2024